

# Nada Hamad

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1403193/nada-hamad-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

68

papers

436

citations

11

h-index

19

g-index

80

ext. papers

787

ext. citations

4.8

avg, IF

3.25

L-index

#	Paper	IF	Citations
68	The untold effect of the combined oral contraceptive pill on anticancer drugs.. <i>Lancet Haematology,the</i> , <b>2022</b> , 9, e10-e11	14.6	
67	The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	1
66	Timing of high dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1,384 patients.. <i>Blood</i> , <b>2022</b> ,	2.2	3
65	Iron deficiency in women: clearing the rust of silence.. <i>Lancet Haematology,the</i> , <b>2022</b> , 9, e247-e248	14.6	
64	Telemedicine for rural and regional patient access to haematology services during the COVID-19 pandemic in Australia.. <i>Lancet Haematology,the</i> , <b>2022</b> , 9, e325-e326	14.6	1
63	Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.. <i>New England Journal of Medicine</i> , <b>2021</b> ,	59.2	26
62	Update of Multicenter, Retrospective Evaluation of Overall Response and Failure Free Survival Following Ruxolitinib Therapy for Heavily Pre-Treated Chronic Gvhd Patients with Steroid-Failure: A Proposal of Risk Score Model for Failure-Free Survival. <i>Blood</i> , <b>2021</b> , 138, 3905-3905	2.2	
61	Outcomes for Allogeneic Stem Cell Transplantation in Secondary AML Are Inferior to De Novo AML and Are Independent of the Disease Risk Index. <i>Blood</i> , <b>2021</b> , 138, 3958-3958	2.2	
60	Capturing the Lived Experiences of Women with Lymphoma in Pregnancy: An Australasian Lymphoma Alliance Study. <i>Blood</i> , <b>2021</b> , 138, 4099-4099	2.2	0
59	Real-World Outcomes of Aggressive B-Cell Non-Hodgkin Lymphoma in People Living with HIV (PLWH) Treated in Australia: An Australasian Lymphoma Alliance Study. <i>Blood</i> , <b>2021</b> , 138, 1456-1456	2.2	
58	Lymphoma during Pregnancy: A Multicentre Study By the Australasian Lymphoma Alliance. <i>Blood</i> , <b>2021</b> , 138, 882-882	2.2	1
57	Systematic Omission of Pregnant and Lactating Women from Malignant Haematology Trials Perpetuates a Cycle of Exclusion, Data Shortage and Disadvantage. <i>Blood</i> , <b>2021</b> , 138, 3050-3050	2.2	0
56	Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma Alliance. <i>HemaSphere</i> , <b>2021</b> , 5, e648	0.3	0
55	Qualitative study of nuclear medicine physicians' perceptions of positron emission tomography/computed tomography in pregnant patients with cancer. <i>Internal Medicine Journal</i> , <b>2021</b> , 51, 1722-1726	1.6	0
54	Integrated electronic health record facilitates a safer and more efficient rural outreach haematology service. <i>Internal Medicine Journal</i> , <b>2021</b> , 51, 1869-1875	1.6	1
53	Myeloid somatic mutation panel testing in myeloproliferative neoplasms. <i>Pathology</i> , <b>2021</b> , 53, 339-348	1.6	0
52	Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma. <i>Future Oncology</i> , <b>2021</b> , 17, 1295-1310	3.6	1

51	COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. <i>Internal Medicine Journal</i> , <b>2021</b> , 51, 763-768	1.6	2
50	Trials and tribulations: including women in cancer clinical research. <i>Lancet Haematology</i> , <b>2021</b> , 8, e477-e478	14.6	1
49	Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. <i>JAMA Oncology</i> , <b>2021</b> , 7, 993-1003	13.4	5
48	Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study. <i>Journal of Hematology and Oncology</i> , <b>2021</b> , 14, 111	22.4	3
47	Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience. <i>British Journal of Haematology</i> , <b>2021</b> , 192, 1049-1053	4.5	13
46	Letter to the Editor Regarding "Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia". <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 190-191		
45	Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination - A risk-benefit analysis for people. <i>Vaccine</i> , <b>2021</b> , 39, 4784-4787	4.1	11
44	Australia and New Zealand Transplant and Cellular Therapies COVID-19 vaccination consensus position statement. <i>Internal Medicine Journal</i> , <b>2021</b> , 51, 1321-1323	1.6	1
43	One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. <i>Haematologica</i> , <b>2021</b> ,	6.6	11
42	Managing haematological malignancies in pregnant women. <i>Lancet Haematology</i> , <b>2021</b> , 8, e623-e624	14.6	1
41	Good Engraftment but Quality and Donor Concerns for Cryopreserved Hemopoietic Progenitor Cell Products Collected During the COVID-19 Pandemic. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> ,		1
40	Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic. <i>Internal Medicine Journal</i> , <b>2020</b> , 50, 667-679	1.6	25
39	Bone Marrow Transplant Society of Australia and New Zealand COVID-19 consensus position statement. <i>Internal Medicine Journal</i> , <b>2020</b> , 50, 774-775	1.6	0
38	Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. <i>Lancet Haematology</i> , <b>2020</b> , 7, e511-e522	14.6	97
37	Hematopoietic Stem Cell Transplant Recipients Surviving at Least 2 Years from Transplant Have Survival Rates Approaching Population Levels in the Modern Era of Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1711-1718	4.7	3
36	Unrelated Donor Transplant Recipients Given Thymoglobuline Have Superior GRFS When Compared to Matched Related Donor Recipients Undergoing Transplantation without ATG. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1868-1875	4.7	4
35	A Phase II, Open-Label, Single Arm Trial to Assess the Efficacy and Safety of the Combination of Tisagenlecleucel and Ibrutinib in Mantle Cell Lymphoma (TARMAC). <i>Blood</i> , <b>2020</b> , 136, 34-35	2.2	1
34	Survival Outcomes for Plasmablastic Lymphoma: An International, Multicentre Study By the Australasian Lymphoma Alliance. <i>Blood</i> , <b>2020</b> , 136, 1-2	2.2	0

33	Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study. <i>Blood</i> , <b>2020</b> , 136, 11-12	2.2	0
32	Allogeneic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma Can Achieve Durable Remissions: An Australasian Bone Marrow Transplant Recipient Registry Study. <i>Blood</i> , <b>2020</b> , 136, 18-19	2.2	
31	Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma Can Achieve Durable Remission and Myeloablative Conditioning Is Associated with Inferior Survival: An Australasian Bone Marrow Transplant Recipient Registry Study. <i>Blood</i> , <b>2020</b> , 136, 7-8	2.2	
30	Prolonged Lymphopenia and Infection Risk Is Mitigated By Antimicrobial Prophylaxis in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Treated with Bendamustine +/- Anti-CD20 Antibody: The Australasian Lymphoma Alliance Experience. <i>Blood</i> , <b>2020</b> , 136, 47-49	2.2	1
29	A Shared Electronic Health Record in a Rural Setting Maintains Hematological Cancer Services Remotely during the COVID-19 Pandemic. <i>Blood</i> , <b>2020</b> , 136, 5-5	2.2	
28	Improvement in Non-Relapse Mortality Following Allogeneic Transplantation for Chronic Lymphocytic Leukaemia in Australia and New Zealand: An Australasian Bone Marrow Transplant Recipient Registry Study. <i>Blood</i> , <b>2020</b> , 136, 25-26	2.2	
27	Trials in Progress: A Phase I Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants with Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High-Risk Myelodysplastic Syndrome. <i>Blood</i> , <b>2020</b> , 136, 21-21	2.2	
26	Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A Retrospective Analysis from the Australasian Bone Marrow Transplant Recipient Registry. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 2252-2261	4.7	1
25	Variable CD34+ recovery of cryopreserved allogeneic HPC products: transplant implications during the COVID-19 pandemic. <i>Blood Advances</i> , <b>2020</b> , 4, 4147-4150	7.8	15
24	Reproductive outcomes following a stem cell transplant for a haematological malignancy in female cancer survivors: a systematic review and meta-analysis. <i>Supportive Care in Cancer</i> , <b>2019</b> , 27, 4451-4460	3.9	5
23	HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia. <i>Leukemia</i> , <b>2019</b> , 33, 1439-1450	10.7	8
22	Bing Neel Syndrome: Retrospective Australasian Experience of a Rare Treatable Complication of Waldenström Macroglobulinaemia/ Lymphoplasmacytic Lymphoma. <i>Blood</i> , <b>2018</b> , 132, 5325-5325	2.2	1
21	Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b Sadal Study. <i>Blood</i> , <b>2018</b> , 132, 1677-1677	2.2	2
20	Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD. <i>Annals of Hematology</i> , <b>2017</b> , 96, 805-813	2.8	8
19	Novel remote authentication protocol using heart-signals with chaos cryptography <b>2017</b> ,		4
18	Distinctive clinical characteristics and favorable outcomes in patients with large granular lymphocytosis after allo-HCT: 12-year follow-up data. <i>European Journal of Haematology</i> , <b>2017</b> , 99, 160-168	2.8	3
17	Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia. <i>Journal of Translational Medicine</i> , <b>2016</b> , 14, 82	8.5	6
16	Chronic lymphocytic leukaemia, monoclonal B-lymphocytosis and pregnancy: five cases, a literature review and discussion of management. <i>British Journal of Haematology</i> , <b>2015</b> , 168, 350-60	4.5	9

15	Primary Cutaneous Mantle-Cell Lymphoma: A Case Report and Literature Review. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e104-8	2.2	5
14	Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation. <i>American Journal of Hematology</i> , <b>2015</b> , 90, 392-97.1	7.1	14
13	Outcomes of hematopoietic cell transplantation in adult patients with acquired aplastic anemia using intermediate-dose alemtuzumab-based conditioning. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 1722-8	4.7	9
12	BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase. <i>American Journal of Hematology</i> , <b>2014</b> , 89, 626-32	7.1	30
11	Incidence, risk factors, and long-term outcomes of sclerotic graft-versus-host disease after allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 1751-7	4.7	13
10	Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 556-63	4.7	27
9	The risk of polyomavirus BK-associated hemorrhagic cystitis after allogeneic hematopoietic SCT is associated with myeloablative conditioning, CMV viremia and severe acute GVHD. <i>Bone Marrow Transplantation</i> , <b>2014</b> , 49, 1528-34	4.4	43
8	Risk stratification of organ-specific GVHD can be improved by single-nucleotide polymorphism-based risk models. <i>Bone Marrow Transplantation</i> , <b>2014</b> , 49, 649-56	4.4	13
7	HCT-CI Has Prognostic Value in Acute, but Not Chronic Gvhd Specific Survival. <i>Blood</i> , <b>2014</b> , 124, 3915-3915		
6	The Risk Factors for IgG Hypogammaglobulinemia after Allogeneic Hematopoietic Stem Cell Transplantation and Its Impact on Transplant Outcomes. <i>Blood</i> , <b>2014</b> , 124, 3928-3928	2.2	
5	The NIH Chronic Gvhd Global Score and the CIBMTR Risk Score Correlate Well with Failure Free Survival Following Frontline Systemic Corticosteroid Therapy for Chronic Gvhd. <i>Blood</i> , <b>2014</b> , 124, 3925-3925	2.2	
4	Propensity Score Matching Analysis Comparing Reduced Intensity Versus Myeloablative Conditioning in AML/MDS Patients Transplanted with Fludarabine-Busulfan-Low Dose Total Body Irradiation Based Regimen. <i>Blood</i> , <b>2014</b> , 124, 3870-3870	2.2	1
3	Outcomes of Allogeneic Hematopoietic Cell Transplantation In Aplastic Anemia Using Intermediate Dose Alemtuzumab Based-Conditioning. <i>Blood</i> , <b>2013</b> , 122, 2044-2044	2.2	
2	Mycophenolate Compared to Methotrexate As Part of Cyclosporine Based-GVHD Prophylaxis Does Not Affect Transplant Outcomes, Reduces Organ Specific Acute And Chronic GVHD, but Increases The Risk of CMV Viremia In Matched Related Donor Peripheral Blood Stem Cell Transplantation. <i>Blood</i> , <b>2013</b> , 122, 3293-3293	2.2	
1	Incidence, Risk Factors and Allogeneic Stem Cell Transplant Outcomes In Chronic Sclerotic Gvhd: T-Cell Depletion Is Preventive and Peripheral Blood Stem Cell is a Risk Factor, But Not HLA-Mismatch With No Adverse Impact On Transplant Outcomes. <i>Blood</i> , <b>2013</b> , 122, 3293-3293	2.2	